Eagle Health Investments LP
Long book
$476.3M
Q1 2026
Positions
26
Top-10 weight
64%
concentration
Last quarter
+32.7%
SPY +14.8%
Turnover
44%
of book per quarter
Strategy in plain words
auto-generated from filingsEagle Health Investments LP is a concentrated fundamental stock-picker, specialised in healthcare (97% of the long book), running a $476.3M US long book across 26 positions.
The portfolio is concentrated: the top 10 names carry 64% of the portfolio. The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: ARGENX SE - ADR, ICON PLC, INSMED INC, GUARDANT HEALTH INC, BIOMARIN PHARMACEUTICAL INC.
Over the last 9 quarters its long book ran on average 2.1pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
+4.8%
Q2 2024
+9.1%
Q3 2024
-3.3%
Q4 2024
-11.2%
Q1 2025
+8.4%
Q2 2025
+11.8%
Q3 2025
+18.4%
Q4 2025
-11.6%
Q1 2026
+32.7%
Sector allocation
Healthcare 91%
Other 6%
Technology 3%
Long book by quarter
What does Eagle Health own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| ICLR ICON PLC | Healthcare | 358.5K | $39.7M | 8.3% | +45.1% |
| INSM INSMED INC | Healthcare | 224.3K | $36.7M | 7.7% | +6.3% |
| GH GUARDANT HEALTH INC | Healthcare | 310.3K | $28.7M | 6.0% | +9.2% |
| BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 505.8K | $28.6M | 6.0% | +37.9% |
| NTRA NATERA INC | Healthcare | 121.9K | $24.4M | 5.1% | -33.5% |
| SRRK SCHOLAR ROCK HOLDING CORP | Healthcare | 494.0K | $24.3M | 5.1% | +36.0% |
| ILMN ILLUMINA INC | Healthcare | 187.4K | $23.1M | 4.9% | -18.9% |
| 430 TERNS PHARMACEUTICALS INC | — | 412.5K | $21.7M | 4.6% | +49.9% |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 267.0K | $19.8M | 4.2% | +3.0% |
| PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 179.3K | $18.9M | 4.0% | +213.0% |
| RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 884.1K | $18.5M | 3.9% | New |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 293.2K | $18.4M | 3.9% | New |
| FTRE FORTREA HOLDINGS INC | Healthcare | 1.3M | $12.3M | 2.6% | +7.3% |
| KYMR KYMERA THERAPEUTICS INC | Healthcare | 145.8K | $12.1M | 2.5% | +7.0% |
| PRCT PROCEPT BIOROBOTICS CORP | Healthcare | 483.8K | $12.1M | 2.5% | +56.9% |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 119.5K | $11.6M | 2.4% | +3.1% |
| TEM TEMPUS AI INC-CL A | Technology | 256.3K | $11.6M | 2.4% | New |
| ALKS ALKERMES PLC | Healthcare | 238.7K | $8.4M | 1.8% | +191.8% |
| ATAI ATAIBECKLEY INC | Healthcare | 1.7M | $6.1M | 1.3% | New |
| ISRG INTUITIVE SURGICAL INC | Healthcare | 4.4K | $2.0M | 0.4% | Held |
| PCSC PERCEPTIVE CAPITAL SOLUTIONS | Healthcare | 37.7K | $413K | 0.1% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 28 | $571.8M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 6, 2026 | 30 | $455.1M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 7, 2025 | 23 | $380.9M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 12, 2025 | 21 | $405.2M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 12, 2025 | 20 | $385.1M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 12, 2025 | 18 | $407.9M | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 12, 2024 | 25 | $528.0M | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 13, 2024 | 26 | $570.2M | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 14, 2024 | 27 | $538.2M | canonical | SEC ↗ |